| Serial Number | 98072031 |
| Word Mark | NVELOP |
| Filing Date | Wednesday, July 5, 2023 |
| Status | 681 - PUBLICATION/ISSUE REVIEW COMPLETE |
| Status Date | Wednesday, December 11, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, December 31, 2024 |
| Goods and Services | pharmaceutical preparations for gene therapy and gene editing; drug delivery agents that facilitate delivery of pharmaceuticals, namely, drug delivery agents consisting of particles in the nature of virus-like particles that facilitate delivery of a wide range of pharmaceuticals; drug carriers for medical use, namely, drug delivery agents in the form of engineered particles in the nature of virus-like particles that facilitate the delivery of pharmaceutical preparations for delivering drugs to human organs; cell and gene therapy products for increasing protein expression in cells, namely, engineered virus-like particles; pharmaceutical and biological preparations for delivering proteins into cells for the prevention, diagnosis and treatment of genetic diseases, namely, cancer, including hematological and solid tumors, autoimmune diseases, cardiovascular disease, respiratory disease, pulmonary disease, central nervous system diseases and disorders, mitochondrial diseases and disorders, endocrine disorders, gastrointestinal diseases, auditory processing disorders (APD) and hearing loss disorders, inflammatory diseases, acquired and innate immunodeficiencies, kidney disease, liver disease, metabolic diseases and disorders, musculoskeletal disorders, neurodegenerative diseases and disorders, neurological diseases and disorders, brain disorders and diseases, neuromuscular and viral diseases and disorders, blood disorders, bone growth disorders, skin disorders, arthritis, hypertension, pain, stroke, obesity and diabetes; pharmaceutical and biological preparations for delivering therapeutic proteins for treatment of cancer, including hematological and solid tumors, autoimmune diseases, cardiovascular disease, respiratory disease, pulmonary disease, central nervous system diseases and disorders, mitochondrial diseases and disorders, endocrine disorders, gastrointestinal diseases, genetic diseases and disorders, auditory processing disorders (APD) and hearing loss disorders, inflammatory diseases, acquired and innate immunodeficiencies, kidney disease, liver disease, metabolic diseases and disorders, musculoskeletal disorders, neurodegenerative diseases and disorders, neurological diseases and disorders, brain disorders and diseases, neuromuscular and viral diseases and disorders, blood disorders, bone growth disorders, skin disorders, arthritis, hypertension, pain, stroke, obesity and diabetes |
| Goods and Services | medical and scientific research in the fields of gene therapy, gene editing, genome engineering, gene modulation, genetic diseases, gene therapy, cell therapy, therapeutic proteins, protein expression, protein delivery and drug delivery; services in the field of production of cell therapies namely, scientific research and medical research in the field of gene editing technology featuring gene-editing and protein delivery; pharmaceutical research services; pharmaceutical drug development services; medical and scientific research for the treatment of genetic diseases and disorders |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Saturday, August 5, 2023 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Saturday, August 5, 2023 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Nvelop Therapeutics, Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Boston, MA 02199 |
| Event Date | Event Description |
| Saturday, July 8, 2023 | NEW APPLICATION ENTERED |
| Saturday, August 5, 2023 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Saturday, March 16, 2024 | ASSIGNED TO EXAMINER |
| Thursday, March 21, 2024 | NON-FINAL ACTION WRITTEN |
| Thursday, March 21, 2024 | NON-FINAL ACTION E-MAILED |
| Thursday, March 21, 2024 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Monday, June 10, 2024 | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS |
| Monday, June 10, 2024 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Monday, June 10, 2024 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Monday, June 10, 2024 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Thursday, June 20, 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Thursday, June 20, 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Thursday, June 20, 2024 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Saturday, July 13, 2024 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Saturday, July 13, 2024 | NON-FINAL ACTION WRITTEN |
| Saturday, July 13, 2024 | NON-FINAL ACTION E-MAILED |
| Monday, October 7, 2024 | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED |
| Monday, October 7, 2024 | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED |
| Friday, November 1, 2024 | PRIORITY ACTION E-MAILED |
| Friday, November 1, 2024 | PRIORITY ACTION WRITTEN |
| Friday, November 1, 2024 | NOTIFICATION OF PRIORITY ACTION E-MAILED |
| Monday, November 25, 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Monday, November 25, 2024 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Tuesday, November 26, 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Friday, December 6, 2024 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, December 25, 2024 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |